From penicillin G to tricyclic beta-lactams;Von penicillin G zu tricyclischen β-lactamen

Pharmazie in Unserer Zeit

Volumn 35, Issue 5, 2006, Pages 410-414

  Holzgrabe, Ulrike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBACEPHEM DERIVATIVE; CARBAPENEM; CEFTOBIPROLE; CEPHALOSPORIN; CLAVULANIC ACID; ERTAPENEM; LATAMOXEF; MONOBACTAM DERIVATIVE; PENEM DERIVATIVE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; SANFETRINEM; SANFETRINEM CILEXETIL; TICARCILLIN; TRIBACTAM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLIN RESISTANCE; BACTERIUM; CHEMISTRY; DRUG EFFECT; REVIEW; STRUCTURE ACTIVITY RELATION;

BACTERIA; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORINS; HUMANS; PENICILLIN G; PENICILLINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33749328561     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200600186     Document Type: Article

References (15)

1. Sorbera, L.A., Castaner, J., Castaner, R.M.: Ceftibiprole/Ceftobiprole Medocaril. Drug. Fut. 30 (2005), 11-22.
2. Buynak, J.D.: Understanding the longevity of the β-lactam antibiotics and antibiotic/β-lactamase inhibitor combinations. Biochem. Pharmacol. 71 (2006), 930-940.
3. Dalhoff, A., Nasu, T., Okamoto, K.: Target Affinities of Faropenem to and its impact on the morphology of grain-positive and gram-negative bacteria. Chemotherapy 49 (2003), 172-183.
4. Dalhoff, A., Janjic, N., Echols, R.: Redefining penems. Biochem. Pharmacol. 71 (2006), 1085-1095.
5. Critchley, I.A., Karlowsky, J.A., Draghi, D.C., Jones, M.E., Thornsberry, C., Murfitt, K., Sahm, D.F.: Activities of Faropenem, an oral β-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Ag. Chemother. 46 (2002), 550-555.
6. Jones, R.N., Critchley, I.A., Whittington, W.L.H., Janjic, N., Pottumarthy, S.: Activity of faropenem against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. Diagn. Microbiol. Inf. Disease 53 (2005), 311-317
7. Smith, G.B., Dezeny, G.C., Douglas, A.W.: Stability and kinetics of degradation of imipenem in aqueous solution. J. Pharm. Sci. 79 (1990), 732-740.
8. Viaene, E., Chanteux, H., Servais, H., Mingeot-Leclercq, M.-P., Tulkens, P.M.: Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care unit). Antimicrob. Ag. Chemother. 46 (2002), 2327-2332.
9. Tomaselli, F., Maier, A., Matzi, V., Smolle-Jüttner, F.M., Dittrich, P.: Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob. Ag. Chemother. 48 (2004), 2228-2232.
10. Nix, D.E., Majumdar, A.K., DiNubile, M.J.: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. 53 Suppl.2 (2004), ii23-ii28.
11. Teppler, H., Gesser, R.M., Friedland, I.R, Woods, G.L., Meibohm, A., Herman, G., Mistry, G., Isaacs, R.: Safety and tolerability of ertapenem. J. Antimicrob. Chemother. 53 Suppl.2 (2004), ii75-ii81.
12. Zhao, Z., Qin, X.Z., Reed, R.A.: Identification by LC/MSn of degradates of a novel carbapenem antibiotic in an aqueous matrix. J. Pharm. Biomed. Anal. 29 (2002), 173-181.
13. Fritsche, T.R., Stilwell, M.G., Jones, R.N.: Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11 (2005), 974-984.
14. Traczewski, M.M., Brown, S.D. In vitro activity of doripenem against Pseudomonas aeruginosa and Brukholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Ag. Chemother. 50: (2006) 819-821.
15. Marini, A., Berbenni, V., Bruni, G., Sinistri, C., Maggioni, A., Orlandi, A., Villa, M.: Physico-chemical characerization of a novel tricyclic β-lactam antibiotic. J. Pharm. Sci. 89 (2000), 232-240.